SCHEDULE: Goldman Sachs Discloses Tango Therapeutics Stake

Goldman Sachs Group, Inc. and Goldman Sachs & Co. LLC have filed a Schedule 13G, reporting beneficial ownership of 6.0% of Tango Therapeutics, Inc. common stock as of June 30, 2026.

Summary

• The filing is a Schedule 13G, an informational filing required for beneficial ownership of more than 5% of a class of a company's securities.
• The reporting persons are The Goldman Sachs Group, Inc. and Goldman Sachs & Co. LLC.
• As of June 30, 2026, the reporting persons beneficially owned 9,742,402.80 shares of Tango Therapeutics, Inc. common stock.
• This represents 6.0% of the class of securities.
• Goldman Sachs & Co. LLC is identified as a broker-dealer and investment adviser.
• The filing confirms that the securities were acquired and are held in the ordinary course of business and not for the purpose of influencing control of the issuer.

Sentiment

Score: 3

Explanation: StockSavvy.ai views this as a neutral filing, primarily an administrative disclosure of beneficial ownership by a financial institution, with no new operational or financial performance data.

Positives

• The filing indicates a significant institutional investor, Goldman Sachs, holds a stake in Tango Therapeutics.
• The disclosure is made in accordance with regulatory requirements, ensuring transparency.

Negatives

• The filing does not provide any new operational or financial performance data for Tango Therapeutics.
• It is a routine disclosure and does not offer insights into the company's strategic direction or market position.

Risks

• The filing does not explicitly mention any risks related to Tango Therapeutics' business operations or financial health.

Future Outlook

The filing does not contain any forward-looking statements or guidance regarding Tango Therapeutics' future performance.

Management Comments

• The securities referred to above were acquired and are held in the ordinary course of business and were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under 240.14a-11.

Industry Context

StockSavvy.ai notes that Schedule 13G filings are common for large financial institutions like Goldman Sachs when they accumulate a significant stake in a publicly traded company, often as part of their asset management or trading activities. This filing itself does not provide insight into Tango Therapeutics' specific industry performance but rather reflects institutional investment interest.

Stakeholder Impact

• Shareholders: The filing confirms a significant institutional investor's presence, which can be viewed positively as a sign of confidence, but it does not directly impact current share value or dividends.
• Creditors: No direct impact is indicated.
• Employees: No direct impact is indicated.
• Suppliers/Customers: No direct impact is indicated.

Next Steps

• The filing itself does not outline specific next steps for Tango Therapeutics.
• Goldman Sachs will continue to hold its position as disclosed, subject to its investment strategy and regulatory requirements.

Key Dates

Keywords

Tango Therapeutics, Schedule 13G, beneficial ownership, Goldman Sachs, institutional investor, common stock, SEC filing